More than four years after handing over nearly $400 million to buy Viralytics, Merck is axing the sole therapy acquired in the deal.
The week’s biotech news included positive results from a study of Merck’s virus-based Cavatak in bladder cancer; a modified CRISPR gene editing system to treat hearing loss; and insight into cancer resistance in bats that could spark new treatments for people.
Viralytics Limited News Full Screen View
Market Place
Share